More News

Mechanism for weakening a bacterium responsible for food poisoning

Jim Cornall -
Scientists from the Department of Microbiology of the University of Malaga in Spain, also members of the Institute of...

New research could lead to vaccine for severe diarrhoea

Jim Cornall -
Research led by the University of Bergen (UiB) in Norway and NORCE may help pave the way for a...

BioArctic and Lilly sign research agreement

Jim Cornall -
BioArctic AB (publ) has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential...

Biogen boosts immunology pipeline through $1bn RayThera acquisition

Jim Cornall -
Biogen Inc. and RayThera Inc., a private biotechnology company focused on discovering and developing small molecule therapies in immunology,...

Brain tau spreads differently in early- and late-onset Alzheimer’s disease

Jim Cornall -
The amount and distribution of the tau protein in the brain differs between early and late-onset Alzheimer's disease. This...

Base to Base biotech podcast 65: Giving medicine a genetic camouflage

Jim Cornall -
This week, we have a conversation with Houdini Bio CEO and co-founder Jonathan Cohen-Gold. Base to Base biotech podcast 65:...

Vedana Therapeutics launches to develop migraine therapies

Jim Cornall -
Vedana Therapeutics, a biotechnology company developing next-generation therapies for migraine prevention, has emerged from stealth with $46m in Series...

Memento Medicines launches with $93m to develop antibody therapy for retinal diseases

Jim Cornall -
Memento Medicines, Inc., a privately-held biotech company developing biologic therapies for retinal diseases, has complete a $93m Series A...

Meteor Biotech joins brain organoids consortium

Jim Cornall -
Meteor Biotech, which works in spatially resolved cell isolation technologies for advanced biomedical research, is set to participate in...

Can food influence gene activity?

Jim Cornall -
A new international clinical intervention study published in Clinical Nutrition reveals the molecular and transcriptomic mechanisms through which a...

Lab-engineered proteins: a promising treatment for liver disease

Jim Cornall -
A research group led by CIC biomaGUNE’s Ikerbasque research professor Aitziber L. Cortajarena has developed an innovative anti-fibrotic and...

Insilico Medicine And SK Biopharmaceuticals to collaborate in $2.5bn deal

Jim Cornall -
Insilico Medicine and SK Biopharmaceuticals have announced a research and development collaboration at the BIO 2026 International Convention to...

Kither Biotech completes phase 1 trial of inhaled peptide therapy for respiratory diseases

Jim Cornall -
Kither Biotech Pty Ltd and Kither Biotech srl have announced the successful completion of their phase 1 clinical study...

Houdini Bio launches to solve therapeutic and commercial genetic medicine bottlenecks

Jim Cornall -
Houdini Bio has announced its official launch, having raised approximately £1.5m in non-dilutive grant funding and capital from an...

Base to Base biotech podcast 64: Solving logistics challenges

Jim Cornall -
This week, we have a conversation with Bora Pharmaceuticals’ chief commercial officer Jean-Baptiste (JB) Agnus. Base to Base biotech podcast...

Preclinical results for novel therapeutic candidate for rare neurodevelopmental disorders

Jim Cornall -
JW Pharmaceutical has presented preclinical findings and its global development strategy for DDC-02, a therapeutic candidate for rare neurodevelopmental...

Breakthrough in personalised treatments for lung cancer

Jim Cornall -
A study by the University of Barcelona has discovered why the two main types of lung cancer — adenocarcinoma...

Gene therapy prolongs health span

Jim Cornall -
A study developed at the Center for Animal Biotechnology and Gene Therapy (CBATEG) of the Universitat Autònoma de Barcelona...

CancerVax demonstrates full nanoparticle delivery

Jim Cornall -
CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that “tricks” the body’s immune system into fighting...

Nuvalent to be acquired by GSK for $10.6bn

Jim Cornall -
Nuvalent, Inc. has entered into a definitive agreement to be acquired by GSK for $10.6bn. Nuvalent is a clinical-stage precision...

FCS Foundation becomes The Foundation for Triglyceride Disorders

Jim Cornall -
The FCS Foundation has rebranded to The Foundation for Triglyceride Disorders, reflecting the organisation's expanded commitment to supporting individuals...